Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial

BACKGROUND: Preclinical studies recently showed that the mineralocorticoid antagonist spironolactone acts also as an antagonist of the NRG1-ERBB4 signaling pathway and improves schizophrenia-like behaviour in Nrg1 transgenic mouse model. As this signaling pathway is critically linked to the pathophy...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Contemp Clin Trials Commun
Autores principales: Hasan, Alkomiet, Roeh, Astrid, Leucht, Stefan, Langguth, Berthold, Hansbauer, Maximilian, Oviedo-Salcedo, Tatiana, Kirchner, Sophie K., Papazova, Irina, Löhrs, Lisa, Wagner, Elias, Maurus, Isabel, Strube, Wolfgang, Rossner, Moritz J., Wehr, Michael C., Bauer, Ingrid, Heres, Stephan, Leucht, Claudia, Kreuzer, Peter M., Zimmermann, Stephanie, Schneider-Axmann, Thomas, Görlitz, Thomas, Karch, Susanne, Egert-Schwender, Silvia, Schossow, Beate, Rothe, Philipp, Falkai, Peter
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7013159/
https://ncbi.nlm.nih.gov/pubmed/32072071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.conctc.2020.100537
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares